Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2282 • ACR Convergence 2024
Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response
M. Elaine Husni, Judy Zhang, Jean Lin, Yuxuan Jin and Unnikrishnan Chandrasekharan, Cleveland Clinic, Cleveland, OH
Background/Purpose: The development of a personalized medicine approach to identify responders and non-responders to tumor necrosis factor alpha (TNFα) inhibiting agents for rheumatoid arthritis (RA)…
Abstract Number: 2566 • ACR Convergence 2024
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
andriko Palmowski¹, Zhivana Boydzhieva², Paula Hoff³, Sandra Hermann³, burkhard Muche³, David Simon⁴, Gerhard Krönke³, Edgar Wiebe⁵ and FRANK HARTMUT DR. BUTTGEREIT⁵, ¹Charité - Universittsmedizin Berlin, Berlin, Germany, ²Charité Universittsmedizin, Berlin, Germany, ³Rheumatology, Charité, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
Abstract Number: 2674 • ACR Convergence 2024
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
christina Charles-Schoeman¹, Patrick Zueger², Erin Blondell², Siran Fang², Yi Peng², Manish Jain³ and John Tesser⁴, ¹UCLA Medical Center, Santa Monica, CA, ²AbbVie Inc, North Chicago, IL, ³Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, ⁴Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ
Background/Purpose: For patients with rheumatoid arthritis (RA), current ACR guidelines recommend evaluating treatment response within 3 months of initiating a new therapy. In patients who…
Abstract Number: 0007 • ACR Convergence 2024
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Ryota Sato¹, Mitsuhiro Akiyama², Koichi Oshita³, Yuko Kawano³, Yuki Imura³, Piruzyan Mariam⁴, Manami Kikuchi³, Mikako Murase³, Sachiko Mochiduki³, Naohiro Hashimoto³, Masayuki Watanabe³, Keiko Yoshimoto⁵, Tsutomu Takeuchi⁶, Kenji Chiba⁷ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Brighton, MA, ²Keio University School of Medicine, Palo Alto, CA, ³Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
Abstract Number: 0046 • ACR Convergence 2024
Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies
Jeba Atkia Maisha¹, Alina Sememenko², Jun Kim², Mario Navarrete², XIAOBO MENG¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Rheumatoid Arthritis (RA) begins after a prolonged preclinical phase which is marked by the development of RA antibodies, typically against citrullinated proteins (ACPA). The…
Abstract Number: 0064 • ACR Convergence 2024
Anti-Citrullinated Protein Antibodies Arise During Affinity Maturation of Germline-Encoded Antibodies to Carbamylated Proteins in Rheumatoid Arthritis
Marta Escarra-Senmarti¹, Michael Chungyoun², Dylan Ferris¹, Jeffrey Gray² and Felipe Andrade³, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²The Johns Hopkins Whiting School of Engineering, Baltimore, MD, ³The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The production of antibodies to modified self-antigens is a hallmark in rheumatoid arthritis (RA). Antibodies to citrullinated (ACPAs) and carbamylated proteins (CarP) are of…
Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Fizza Zulfiqar¹, Morgan Steele², Sharanya Shre Ezhilarasan Santhi³, Bryanna Singh², Jaisal Brar³, Sumit Raut³, Prami Nakarmi³, Samhitha Bitla Reddy³, Ojo Ayomide³, Bashar Roumia³, Fariha Tareen³, Nathan Crook³, Vanessa Drust³, Ahmed Fawzy Mohamed³, Asad Mohammad Jani³, Jennifer Orejuela³, Siena Captain³, Nikhil Vojalla³, Muhammad Bilal⁴, Rida Fatima⁴, Sanjana Kesireddy³, Paige Misner³, Rishab Prabhu³, Camelia Arsene³, Jawad Bilal⁵ and Jacky Duong³, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²Trinity Health Oakland, Pontiac, MI, ³Trinity Health Oakland, Pontiac, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Southeast Tucson, Clinician Rheumatologist, Tuscon
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…
Abstract Number: 0233 • ACR Convergence 2024
Comparisons of Ga-FAPI and FDG PET/CT with X-ray Imaging in the Assessment of Rheumatoid Arthritis Patients
Jiana Chen¹, Dan Yang¹, Ziyue Zhou², Yaping luo³ and Huaxia Yang¹, ¹Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ³Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China., Beijing, China
Background/Purpose: The imaging techniques for assessing rheumatoid arthritis (RA), including x-ray, musculoskeletal ultrasound, MRI and positron emission tomography/computed tomography (PET/CT). Fibroblast-like synoviocyte cells, which are…
Abstract Number: 0429 • ACR Convergence 2024
Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition
Rashmi Dhital¹, Kerri Bertrand², Essi Heinonen³ and Christina Chambers⁴, ¹UC San Diego, Brentwood, TN, ²UC San Diego, San Diego, CA, ³UC San Diego, La Jolla, CA; Karolinska Institutet, Stockholm, Sweden, San Diego, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic inflammation in autoimmune rheumatic diseases (ARDs) may alter human milk composition, akin to changes observed in other inflammatory states, indirectly impacting infant health,…
Abstract Number: 0467 • ACR Convergence 2024
Lung Involvement in Early Rheumatoid Arthritis, Analysis of ERA UCLouvain Brussels FINDRA Cohort
FROIDURE Antoine¹, DOYEN Marie², PERROT Marie¹, GHAYE Benoit³, SAPART Emilie⁴, BEARZATTO Bertrand⁵, DURANT Jean-François⁵, AMBROISE Jérôme⁵, GALA Jean-Luc⁵, ZAN Deniz³, AVRAMOVSKA Aleksandra⁴, SOKOLOVA Tatiana⁴, KOENIG Sandra² and DUREZ Patrick⁴, ¹Pulmonology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Radiology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁵Institute de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium
Background/Purpose: The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. We set up a prospective study to detect ILD, bronchiolitis and nodules in…
Abstract Number: 0484 • ACR Convergence 2024
Cluster Analysis Based on Joint Characteristics: A Study of Joint Involvement Profiles in Early Rheumatoid Arthritis (ERA) Patients in China
Yafang Deng¹, Chen Yu², Lin Qiao¹, Nan Jiang¹, Yanhong Wang³, Xinping Tian¹, Qian Wang¹, Mengtao Li⁴ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ³Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disorder characterized by aggressive articular damage, and articular symptoms are often the initial and significant clinical…
Abstract Number: 0501 • ACR Convergence 2024
How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)
Delphine Sophie Courvoisier¹, Yacine Mrad¹, Denis Mongin¹, Romain Aymon², Roberto Caporali³, Denis Choquette⁴, Catalin Codreanu⁵, Louis Coupal⁴, Doreen Huschek⁶, Kimme Hyrich⁷, Florenzo Iannone⁸, Tore K. Kvien⁹, Monika Mustak¹⁰, Dan Nordstrom¹¹, Nina Trokovic¹², Lucia Otero-Varela¹³, Karel Pavelka¹⁴, Manuel Enrique Pombo Suarez¹⁵, Sella A. Provan¹⁶, Ana Maria Rodrigues¹⁷, Ziga Rotar¹⁸, Prodromos Sidiropoulos¹⁹, Anja Strangfeld²⁰, Jakub Závada¹⁴, Sizheng Zhao²¹, Axel Finckh¹ and Kim Lauper¹, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospitals, Collonges-sous-Salève, France, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Rhumadata™, Montreal, QC, Canada, ⁵University of Medicine and Pharmacy, Bucharest, Romania, ⁶German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany, ⁷Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁸Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰Department of Internal Medicine II, Kaiser Franz Josef Hospital, Vienna, Austria, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Department of Medicine and Rheumatology ROB-FIN, Helsinki University Hospital, Helsinki, Finland, ¹³Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹⁵Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ¹⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁷Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁸University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, ²⁰German Rheumatism Research Center (DRFZ) Berlin and Charité University Medicine, Berlin, Germany, ²¹Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom
Background/Purpose: JAK-inhibitors (JAKi) have demonstrated a rapid onset of action; however, it is unclear how they compare to other targeted therapies in rheumatoid arthritis (RA).…
Abstract Number: 0517 • ACR Convergence 2024
Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung², Chang-Hee Suh³ and Hyoun-Ah Kim¹, ¹Ajou university school of medicine, Suwon, South Korea, ²Ajou University of medical school, Suwon, South Korea, ³Ajou University Hospital, Suwon, South Korea
Background/Purpose: The use of biologic disease-modifying antirheumatic drugs (bDMARDs) has revolutionized the management of rheumatoid arthritis (RA), despite their efficacy being occasionally limited by infusion-related…
Abstract Number: 0535 • ACR Convergence 2024
Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients
Pauline Bovens¹, Luuk Van Esveld², Maike Wientjes¹, Noortje van Herwaarden³, David Ten Cate⁴, Eward Melis³, Nienke Lesuis⁵, Bart van den Bemt⁶ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Utrecht, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Sint Maartenskliniek, Rotterdam, Netherlands, ⁵Hospital Group Twente, Almelo, Netherlands, ⁶Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: It has been demonstrated that pretreatment with intravenous glucocorticoids can prevent infusion-related reactions (IRR) that may occur in RA patients receiving rituximab infusions [1].…
Abstract Number: 0853 • ACR Convergence 2024
Lung Ultrasound in Rheumatoid Arthritis and Systemic Sclerosis: Accuracy of B-line and Pleural Assessment
Jesús Loarce¹, Ana García de Vicente¹, Javier Arechavala Hita¹, Carlos de La Puente Bujidos¹, Juan Rigual¹, Francisco Javier Bachiller Corral² and Mónica Vázquez Díaz¹, ¹Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ²Ramon y Cajal University Hospital, Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent and severe complication of rheumatoid arthritis (RA) and systemic sclerosis (SSc). Although computerized tomography (CT) is considered…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].